Alan Reichman, MD
Family Medicine · Sugar Land, TXNPI 1245328376
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 328 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,463 and has fallen 98.5% since, to $22 in 2025.
Across 328 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$888
- Abbott$735
- AstraZeneca$464
- Merck$408
- AbbVie$290
- Sanofi-aventis U.S. LLC$255
- plus $3K from 33 others
Across 2,206 payments — averaging $1083.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$1.8M
- Ipsen Innovation$227K
- Novartis$152K
- Pfizer$53K
- GSK$33K
- Sanofi US Services Inc.$29K
- plus $58K from 5 others
What the payments were for
- Food & beverage$5,44898%
- Education$1142%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 51 | $888 |
| Abbott | 49 | $735 |
| AstraZeneca | 30 | $464 |
| Merck | 33 | $408 |
| AbbVie(2 entities) | 13 | $290 |
| Sanofi-aventis U.S. LLC | 15 | $255 |
| GSK | 14 | $243 |
| Boehringer Ingelheim | 15 | $229 |
| Pfizer | 10 | $211 |
| Amgen | 9 | $172 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $151 |
| Lilly USA, LLC | 8 | $148 |
| Bayer | 7 | $143 |
| Optinose US, Inc. | 7 | $143 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $141 |
| Dexcom, Inc. | 6 | $136 |
| Astellas Pharma US Inc | 4 | $87 |
| Biohaven Pharmaceuticals, Inc. | 4 | $83 |
| Amarin Pharma, Inc. | 4 | $67 |
| Esperion Therapeutics, Inc. | 3 | $62 |
| Companion Medical, Inc. | 2 | $45 |
| Johnson & Johnson | 3 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $45 |
| Kowa Pharmaceuticals America, Inc. | 3 | $40 |
| Eisai Inc. | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 1 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Medtronic | 2 | $31 |
| Edwards Lifesciences | 1 | $28 |
| Mylan Specialty L.p. | 1 | $23 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Althera Pharmaceuticals LLC | 1 | $18 |
| Insulet Corporation | 1 | $17 |
| Ascensia Diabetes Care US Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
| Cequr Corporation | 1 | $12 |
How this compares
$5,562 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 62 | $67,368 |
| OzempicSemaglutide | 28 | $30,630 |
| JardianceEmpagliflozin | 25 | $29,692 |
| EliquisApixaban | 34 | $27,838 |
| TradjentaLinagliptin | 25 | $21,083 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $14,723 |
| JanuviaSitagliptin Phosphate | 17 | $14,151 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 13 | $9,048 |
| Atorvastatin Calcium | 597 | $6,021 |
| Rosuvastatin Calcium | 310 | $5,864 |
| CreonLipase/Protease/Amylase | 13 | $5,721 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $4,275 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 66 | $3,323 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 70 | $3,264 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 81 | $3,263 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Symbicort | $464 | $71,64374 claims |
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr | $229 | $59,82363 claims |
| Novo NordiskOzempic | $888 | $30,63028 claims |
| MerckJanumet, Januvia | $408 | $28,87434 claims |
| PfizerEliquis | $211 | $27,83834 claims |
| AbbVieCreon, Synthroid | $290 | $8,62850 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Sugar Land
- Anne Marie Ponce de LeonSugar Land$109K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.